---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-020973"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:27:44.476728+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch

## Summary
- Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
- Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.
- Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.
- Follows earlier $16.6M public offering closed earlier in June 2025.

## SEC filing metadata
- accession: 0001437749-25-020973
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/aytu20250611_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-020973
- JSON: https://secwatch.observer/filing/0001437749-25-020973.json
- Plain text: https://secwatch.observer/filing/0001437749-25-020973.txt

## Key facts
- Debt Financings
  AYTU BIOPHARMA, INC amended revolving credit of $1.5 million incremental advance with Eclipse Business Capital LLC at SOFR plus 5.50% maturing June 12, 2029.
  - Instrument: revolving credit
  - Principal: $1.5 million incremental advance
  - Counterparty: Eclipse Business Capital LLC
  - Rate: SOFR plus 5.50%
  - Maturity: June 12, 2029
  - Event: amendment
  source text: extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm
- Debt Financings
  AYTU BIOPHARMA, INC amended term loan of outstanding principal amount of $13.0 million with Eclipse Business Capital LLC maturing June 12, 2029.
  - Instrument: term loan
  - Principal: outstanding principal amount of $13.0 million
  - Counterparty: Eclipse Business Capital LLC
  - Maturity: June 12, 2029
  - Event: amendment
  source text: extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.